生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | The FGFR (fibroblast growth factors receptor) superfamily with its 18 ligands and four receptors has been implicated in cancer, inflammation, and the escape of tumor vascularization from VEGF (vascular endothelial growth factor) inhibitor treatment. SSR128129E is a multi-FGFR signaling inhibitor with an IC50 value of 1.9 μM for FGFR1. In human umbilical venous endothelial cells (HUVECs) expressing FGFR1, SSR128129E inhibited FGF2-induced EC (endothelial cell) proliferation (IC50: 31 ± 1.6 nM), migration (IC50: 15.2 ± 4.5 nM), and lamellipodia formation in a dose dependent manner. In arthritic mice, oral administration of SSR128129E (30 mg/kg/day) reduced the number of limbs affected by redness, swelling, and deformity. Moreover, SSR128129E and αVEGFR2 each inhibited Panc02 tumor growth by 40%, while the combination treatment inhibited tumor growth by 70%[3]. | ||
作用机制 | SSR128129E binds to the extracellular FGFR domain[3]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.89mL 0.58mL 0.29mL |
14.44mL 2.89mL 1.44mL |
28.88mL 5.78mL 2.89mL |
参考文献 |
---|